Pharma Leaders
Refine Search
Latest Pharma Leaders News & Features
Pharmaceutical
A Q&A with the man who heads the UK business of the privately-held Italian drugmaker. 3 May 2024
Biotechnology
This week in The Pharma Letter Podcast, we are speaking with the chief executive of British drug development company Ellipses Pharma. 23 January 2024
Biotechnology
On Tuesday, US biotech company Novavax, which is advancing protein-based vaccines with its Matrix-M adjuvant, announced a timely update with its Nuvaxovid XBB.1.5 dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted). 1 November 2023
Biotechnology
In the world of outsourced clinical research, ICON is a big fish in a pond full of other increasingly big fish. In this episode of the podcast, we chat with the company’s CCO, George McMillan. 24 October 2023
Biotechnology
The past year has been one of ups and downs for Blueprint Medicines Corporation, a US precision medicines company developing therapies for people with cancer and blood disorders. 20 September 2023
Biotechnology
US biotech Cytokinetics is seeking to develop medicines that treat cardiovascular and neuromuscular diseases of impaired muscle function. 15 August 2023
Biotechnology
The need for medications that bring relief for patients affected by migraine is enormous. 26 July 2023
Biotechnology
Gilead Sciences subsidiary Kite prides itself on being a leader in the development of cell therapies, a claim backed by its pioneering work with Yescarta (axicabtagene ciloleucel). 5 June 2023
Pharmaceutical
As the crowds descend on Chicago for the annual meeting of the American Society of Clinical Oncology (ASCO), The Pharma Letter interviews Eisai chief medical officer Kirk Shepard about his firm’s progress in oncology. 1 June 2023
Biotechnology
Earlier this month, UK biotech Bicycle Therapeutics entered a strategic collaboration with Germany’s Bayer. 26 May 2023
Biotechnology
The progress quietly made by Sino-American biotech company BeiGene with its oral Bruton tyrosine kinase inhibitor (BTKi) Brukinsa (zanubrutinib) since 2019 has been nothing short of remarkable. 30 March 2023
Biotechnology
After an illustrious career as chief scientific officer at Johnson & Johnson, Dr Paul Stoffels is ready for a new chapter in his home country, with Belgian biotech Galapagos. 2 February 2023
Pharmaceutical
In Boston, Massachusetts, one company is now making significant headway in the development of an innovative treatment for serious disorders of the liver. In this week’s episode of The Pharma Letter Podcast, we are joined by Albireo CEO Ron Cooper, for a discussion of his company’s clinical goals and strategic focus. 31 October 2022
Biotechnology
For years, commentators have observed that drug prices in the USA are significantly higher than elsewhere in the world. As the US Congress debates government action, we speak with EQRx chief executive Melanie Nallicheri about her company's market-based solution to high costs. 22 July 2022
Pharmaceutical
One UK-based company is looking to transform the way metabolic disorders are treated, leveraging many of the same AI-based techniques used to great effect elsewhere. MultiOmic Health chief executive Robert Thong discusses his firm's progress. 4 July 2022
Biotechnology
Prothena has an intriguing Alzheimer’s vaccine, dubbed PRX123, which is yet to enter the clinic but which scientists believe could stop the development of both Abeta and tau in the brain. 6 June 2022
Biotechnology
The race to meet sudden, stratospheric demand for new anti-obesity meds is hotting up, but Novo Nordisk CEO Lars Fruergaard Jørgensen takes a collegiate approach. 26 May 2022
Pharmaceutical
In the USA and in Europe, interest in the potential for artificial intelligence to transform different aspects of the life sciences industry is at an all-time high. 12 May 2022
Biotechnology
In recent years there has been an explosion of digital tools in the life sciences, but as with everything in pharma and biotech, their value hinges on the strength of the underlying data, making it essential to capture research in a robust way. One company, Labstep, aims to help scientists achieve this. 5 April 2022
Biotechnology
A feature on the recent fortunes of and prospects for Belgian drugmaker UCB. 25 March 2022
Pharmaceutical
With marketing expenses stretching into the tens or even hundreds of millions of dollars, launching a new product can be a huge challenge for small pharmaceutical companies. 12 July 2019
Biotechnology
As industry majors prepare to make a splash at the upcoming annual meeting of the American Society of Clinical Oncology (ASCO), 2003-founded nanomedicine specialist Nanobiotix hopes it can punch above its weight. 24 May 2019
Pharmaceutical
The runaway success of Adcetris (brentuximab vedotin) ensured the future of Seattle Genetics as an antibody-drug conjugate specialist, but chief executive Clay Siegall has bigger ideas about the breadth of focus for the growing company. 13 December 2018
Pharmaceutical
In the USA alone, more than 10% of adults or adolescents take antidepressants, and fully two-thirds of these people do not respond to first-line treatment, normally a selective serotonin reuptake inhibitor (SSRI) such as Zoloft (sertraline) or Celexa (citalopram). 26 November 2018
Biotechnology
As far as PARP inhibitors are concerned, AstraZeneca stole the show at the annual congress of ESMO this month, with the SOLO-1 trial of Lynparza (olaparib) showing striking data in the first-line maintenance setting for ovarian cancer patients. 9 November 2018
Pharmaceutical
While PARP blocker rivals AstraZeneca and Tesaro chase the prize of a first-line ovarian cancer indication, Clovis Oncology is highlighting what it sees as promising prostate cancer data at this year’s ESMO congress. 19 October 2018
Biotechnology
In the context of a competitive, some say overheated, market for mergers and acquisitions, Johnson & Johnson’s $30 billion purchase of Swiss biotech Actelion could be seen as a value-destructive move for shareholders. 26 September 2018
Pharmaceutical
With World Alzheimer’s Day fast approaching, drugmakers and patients around the world are raising awareness of the challenges faced, and the progress made, in combating this most intractable of conditions. 20 September 2018
Biotechnology
UCB rose 1.2% on Thursday after it published financial results for the first half of 2018. The Belgian drugmaker, which specializes in immunology and neurology, reported 5% sales increases and a 2% rise in overall revenue over the first half of 2017. 26 July 2018
Pharmaceutical
For several years, pharma analysts have predicted varying degrees of impact from nascent blockchain technologies. While some suggest wholesale revolution is in the offing, others anticipate more incremental evolution for a conservative industry that is traditionally resistant to change. 23 July 2018
Biotechnology
When Seattle Genetics announced it had bought exclusive global rights to an an exciting new antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132), shares in the candidate’s developer shot up by a third. 9 July 2018
Pharmaceutical
Pharma companies sometimes need to be aware of advances in wearable technology that threaten to take market share away from their medicines, but such devices can also work well when used in conjunction with drugs. 2 July 2018
Biotechnology
Despite an inexorable rise in the global population of type 2 diabetics, linked to changing lifestyle choices, markets for insulin are becoming ever more competitive. 30 May 2018
Biotechnology
Soaring obesity rates and the accompanying scourge of type 2 diabetes have done wonders for insulin kingpin Novo Nordisk’s bottom line over the last quarter-century. 23 May 2018
Pharmaceutical
Belén Garijo has been the chief executive of the Healthcare business of German life sciences group Merck KGaA since 2015. Speaking to The Pharma Letter, she discusses her company’s quest to overcome the chronic disease ... 17 May 2018
Pharmaceutical
The progress achieved in treating huge swathes of the world’s HIV-infected population in the last 20 to 30 years might give the impression of a therapy area where few challenges remain. 8 May 2018
Biotechnology
A newcomer on the biologics scene expressing a vision to become a global player is nothing new, but it is a bold ambition when coming from CinnaGen, an Iranian biosimilars company that is only just starting its journey in the world’s major pharma markets. 30 April 2018
Biotechnology
Since the inception of the biopharmaceutical age in the 1980s, the share of the market held by large molecules has risen steadily to about a fifth, and growth in the sector continues inexorably at around 7.5%. 23 April 2018
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze